The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi最新文献

Fatal Clinical Course of Hepatic Portal Venous Gas Associated with Thrombosed Abdominal Aortic Aneurysm. 肝门静脉气体与血栓性腹主动脉瘤相关的致命临床过程。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2025.095

Yoon Suk Lee

引用次数: 0

[Achievements and Future Directions of the National Colorectal Cancer Screening Program in Korea]. [韩国国家结直肠癌筛查项目的成就和未来方向]。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2025.123

Tae-Woo Kim, Soo-Young Na

{"title":"[Achievements and Future Directions of the National Colorectal Cancer Screening Program in Korea].","authors":"Tae-Woo Kim, Soo-Young Na","doi":"10.4166/kjg.2025.123","DOIUrl":"https://doi.org/10.4166/kjg.2025.123","url":null,"abstract":"Colorectal cancer (CRC) is one of the most common malignancies worldwide and the second leading cause of cancer-related death. In South Korea, the incidence of CRC has increased alongside rapid socioeconomic development and westernized lifestyles, but it has recently shown a gradual decline, largely due to the National Cancer Screening Program (NCSP). The NCSP, first launched in 1999 and expanded in 2004 to include CRC screening, has reduced the incidence and mortality of colorectal cancer significantly, while improving the five-year relative survival rate. The Korean Colonoscopy Screening Pilot Study (K-COSPI) reported the feasibility, safety, and high acceptability of colonoscopy as a primary screening tool, suggesting the potential to transition to colonoscopy-based national screening. Nevertheless, challenges persist in increasing participation and maintaining high-quality performance because the adenoma detection rate remains a critical indicator of screening effectiveness. Continuous efforts to strengthen public awareness, enhance the quality control of colonoscopy, and develop evidence-based, risk-stratified screening strategies will be essential for sustaining and advancing this exemplary public health achievement.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 2","pages":"104-109"},"PeriodicalIF":0.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Macro-Aspartate Aminotransferase Elevation in a Patient with Chronic Hepatitis B. 慢性乙型肝炎患者巨量天冬氨酸转氨酶升高。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2025.104

Nae-Yun Heo, Jae-Hoon Kim, Seungha Park, Joon Hyuk Choi, Tae Oh Kim, Jin Lee, Yong Eun Park, Kyung Ran Jun

{"title":"Macro-Aspartate Aminotransferase Elevation in a Patient with Chronic Hepatitis B.","authors":"Nae-Yun Heo, Jae-Hoon Kim, Seungha Park, Joon Hyuk Choi, Tae Oh Kim, Jin Lee, Yong Eun Park, Kyung Ran Jun","doi":"10.4166/kjg.2025.104","DOIUrl":"https://doi.org/10.4166/kjg.2025.104","url":null,"abstract":"Although aspartate aminotransferase (AST) is a serum marker of hepatocellular damage in chronic hepatitis, it is difficult to interpret very high AST levels with concurrent low alanine aminotransferase (ALT) levels. Macro-AST is an immunoglobulin-AST complex that can present as aberrant high enzymatic activity without significant inflammation in the liver. Two patients with chronic hepatitis B presented with disproportionate AST elevations. Their plasma samples were precipitated with polyethylene glycol (PEG) and stored at 4°C for macro-AST determinations. In Case 1, PEG precipitation showed 100% removal of AST activity, and refrigerated storage resulted in a ~70% decline over seven days, confirming macro-AST. In Case 2, both tests showed minimal changes, suggesting that macro-AST was unlikely. The AST levels normalized after antiviral therapy, suggesting immune-active hepatitis as the probable cause, but the other contributing factors could not be completely excluded. The abrupt decrease in AST activity after PEG precipitation and during refrigeration storage suggests that relatively high AST values compared to ALT might be attributed to the presence of macro-AST. These non-invasive methods for detecting macroenzymes might help the patient avoid unnecessary further work-ups.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 2","pages":"122-127"},"PeriodicalIF":0.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors for Adverse Circulatory and Respiratory Events in Patients Undergoing Esophageal Endoscopic Submucosal Dissection Under Dexmedetomidine-Based Sedation. 右美托咪定镇静下食管内镜粘膜下夹层患者不良循环和呼吸事件的危险因素。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2025.138

Kenshi Matsuno, Hideaki Miyamoto, Sayoko Tayama, Kotaro Waki, Akira Yamasaki, Yoki Furuta, Ryosuke Gushima, Hideaki Naoe, Yasuhito Tanaka

{"title":"Risk Factors for Adverse Circulatory and Respiratory Events in Patients Undergoing Esophageal Endoscopic Submucosal Dissection Under Dexmedetomidine-Based Sedation.","authors":"Kenshi Matsuno, Hideaki Miyamoto, Sayoko Tayama, Kotaro Waki, Akira Yamasaki, Yoki Furuta, Ryosuke Gushima, Hideaki Naoe, Yasuhito Tanaka","doi":"10.4166/kjg.2025.138","DOIUrl":"https://doi.org/10.4166/kjg.2025.138","url":null,"abstract":"Background/aims: Sufficient sedation is important when performing an endoscopic submucosal dissection (ESD) for an esophageal squamous cell carcinoma (ESCC), and dexmedetomidine (DEX) is being increasingly used. ESD is often performed in elderly patients and those with comorbidities. Therefore, adverse events (AEs) in the circulatory and respiratory systems remain a clinical concern. Despite this, limited data exist on these AEs, so this study was conducted to investigate this issue.Methods: This single-center retrospective study included 526 patients who underwent ESD for ESCC under DEX-based sedation from 2016 to 2023. The study assessed the incidence of AEs in circulatory and respiratory systems, as well as the risk factors associated with these events. Various clinical factors, including the Prognostic Nutritional Index (PNI), were analyzed as candidates.Results: Circulatory AEs occurred in 55 cases (10.5%), including bradycardia (7.2%) and hypotension (4.2%). Univariate and multivariate analyses revealed significant associations of lower PNI (<45) and prolonged procedure time with circulatory AEs (p=0.023 and p=0.008, respectively). Respiratory AEs occurred in 12 cases (2.3%), including respiratory depression (1.0 %) and post-ESD pneumonia (1.5 %) with one fatal case (0.2 %). An analysis of respiratory AEs showed that the elderly (≥80 years) and lower PNI were significant in univariate analysis but not in multivariate analysis (both p=0.07).Conclusions: When performing ESD for ESCC under DEX-based sedation, special caution is needed for patients with lower PNI and the elderly, who are more likely to experience circulatory or respiratory complications.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 2","pages":"110-117"},"PeriodicalIF":0.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Advanced Combination Therapy in Inflammatory Bowel Disease]. 炎症性肠病的高级联合治疗

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2025.142

So Jung Han, Jae Hee Cheon

{"title":"[Advanced Combination Therapy in Inflammatory Bowel Disease].","authors":"So Jung Han, Jae Hee Cheon","doi":"10.4166/kjg.2025.142","DOIUrl":"https://doi.org/10.4166/kjg.2025.142","url":null,"abstract":"Despite the advances in biological and small-molecule therapies, a substantial proportion of patients with inflammatory bowel disease (IBD) experience multiple treatment failures, constituting difficult-to-treat IBD with remission rates plateauing at 30-50%. Advanced combination therapy (ACT), defined as the concomitant use of two advanced therapies with distinct mechanisms of action, has become a strategy to overcome this therapeutic ceiling. This review aims to synthesize the rationale, clinical evidence, safety profile, and practical implementation strategies of ACT in IBD. A narrative review of randomized controlled trials (RCTs), meta-analyses, and real-world observational studies evaluating ACT in IBD was performed, focusing on the mechanistic rationale, efficacy outcomes, safety data, and clinical application strategies. ACT is supported by pharmacokinetic synergy (reduced immunogenicity and improved drug exposure) and pharmacodynamic complementarity (simultaneous blockade of multiple inflammatory pathways). Proof-of-concept RCTs, including VEGA and EXPLORER, along with meta-analyses, revealed higher clinical and endoscopic remission rates with ACT than with monotherapy in refractory populations. The safety profiles are generally comparable to monotherapy, but regimen-specific heterogeneity exists. Although vedolizumab- or ustekinumab-based combinations show favorable long-term safety, regimens including natalizumab or JAK inhibitors warrant caution and close monitoring. Detailed clinical strategies include induction-bridge approaches with JAK inhibitors, safety-anchor strategies with gut-selective agents, mechanistic complementarity strategies for treatment failures, and double-indication strategies for extraintestinal manifestations. ACT is a promising rescue strategy for D2T IBD with encouraging efficacy and acceptable safety. Future research should focus on large-scale RCTs and biomarker-driven strategies to optimize patient selection and treatment protocols for ACT.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 2","pages":"85-103"},"PeriodicalIF":0.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer]. [晚期胆道癌的免疫治疗和靶向治疗]

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2026.021

Inho Lee, Seung Bae Yoon

{"title":"[Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer].","authors":"Inho Lee, Seung Bae Yoon","doi":"10.4166/kjg.2026.021","DOIUrl":"https://doi.org/10.4166/kjg.2026.021","url":null,"abstract":"Biliary tract cancer (BTC), encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder cancer, represents a heterogeneous group of malignancies characterized by an aggressive clinical course and poor prognosis. Systemic chemotherapy with gemcitabine plus cisplatin has remained the standard first-line treatment for more than a decade because most patients are diagnosed at an advanced or unresectable stage, but the associated survival benefit is limited. Recent therapeutic advances have been driven by the integration of immunotherapy and molecularly targeted approaches. Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinically meaningful activity, particularly in combination with cytotoxic chemotherapy, and are increasingly being incorporated into first-line treatment strategies for advanced BTC. Concurrently, comprehensive molecular profiling has revealed substantial genomic heterogeneity and identified actionable alterations, including fibroblast growth factor receptor 2 (FGFR2) fusions, isocitrate dehydrogenase 1 (IDH1) mutations, and human epidermal growth factor receptor 2 (HER2) amplification, enabling the development of precision targeted therapies for selected patient populations. Despite these advances, the therapeutic responses to immunotherapy and targeted agents remain highly variable, and robust predictive biomarkers have yet to be established. Accordingly, optimizing patient selection by integrating molecular and immunologic characteristics has become a critical objective for improving clinical outcomes. This review provides an overview of the recent progress in immunotherapy and targeted therapy for BTC, focusing on pivotal clinical trials, therapeutic efficacy, current limitations, and future perspectives for personalized treatment strategies.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 2","pages":"76-84"},"PeriodicalIF":0.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward Precise Risk Stratification after the Functional Cure of Chronic Hepatitis B. 慢性乙型肝炎功能治愈后的精确危险分层。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-04-25 DOI: 10.4166/kjg.2026.020

Moon Haeng Hur

{"title":"Toward Precise Risk Stratification after the Functional Cure of Chronic Hepatitis B.","authors":"Moon Haeng Hur","doi":"10.4166/kjg.2026.020","DOIUrl":"https://doi.org/10.4166/kjg.2026.020","url":null,"abstract":"Chronic hepatitis B remains a major global health challenge despite the advances in antiviral therapy. Although hepatitis B surface antigen (HBsAg) seroclearance is considered a functional cure, liver-related complications, particularly hepatocellular carcinoma, may still occur after viral clearance. This residual risk reflects the lasting impact of host and liver factors rather than ongoing viral activity. Conventional prediction models have attempted to stratify the residual risk after a functional cure but remain limited in their ability to guide individualized management. Recent advances in machine learning have enabled more precise risk stratification by capturing complex host-driven determinants of the long-term outcomes. These approaches support a shift from uniform surveillance toward risk-adaptive monitoring strategies. Nevertheless, post-cure management is emerging as a new clinical priority as more patients achieve a functional cure. Therefore, a functional cure should be viewed not as the end of the disease, but as the beginning of a phase requiring personalized risk assessment and surveillance.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 2","pages":"71-75"},"PeriodicalIF":0.8,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Follow-up Loss After Curative Gastrectomy for Gastric Cancer: Incidence, Contributing Factors, and Survival Impact. 胃癌根治性胃切除术后随访损失：发生率、影响因素和对生存的影响。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-01-25 DOI: 10.4166/kjg.2025.111

Tae-Han Kim, Ji-Ho Park, Sang-Ho Jeong, Dong Whan Kim, Young Hye Kim, Han-Gil Kim, Jin-Kyu Cho, Jae-Myeong Kim, Seung-Jin Kwag, Young-Tae Ju, Chi-Young Jeong, Young-Joon Lee

{"title":"Follow-up Loss After Curative Gastrectomy for Gastric Cancer: Incidence, Contributing Factors, and Survival Impact.","authors":"Tae-Han Kim, Ji-Ho Park, Sang-Ho Jeong, Dong Whan Kim, Young Hye Kim, Han-Gil Kim, Jin-Kyu Cho, Jae-Myeong Kim, Seung-Jin Kwag, Young-Tae Ju, Chi-Young Jeong, Young-Joon Lee","doi":"10.4166/kjg.2025.111","DOIUrl":"10.4166/kjg.2025.111","url":null,"abstract":"Background/aims: This study examined the incidence, causes, and survival outcomes of follow-up loss (FUL) after a gastrectomy for gastric cancer.Methods: Patients who underwent a curative gastrectomy between January 2016 and May 2019 at a regional tertiary hospital were divided into two groups based on their follow-up (FU) adherence. Patients who maintained a regular FU throughout the five-year period were classified as the FU group, and those who failed to attend their scheduled visits for more than 12 consecutive months were grouped as the FUL group. Telephone interviews were conducted to identify the reasons for FU discontinuation and survival status. The sociodemographic and clinical variables were compared, and the independent predictors and survival outcomes were compared.Results: Among the 435 patients, 137 (31.5%) were in the FUL group, and contact was successful in 131 patients (95.6%). The leading cause of FUL was death from non-gastric cancer causes (40.1%). Independent predictors of FUL were older age (hazard ratio [HR]=1.044, p<0.001), lower body mass index (BMI, HR=0.927, p=0.015), absence of familial support (HR=2.666, p=0.005), and total gastrectomy (HR=1.660, p=0.012). The BMI lost significance in sensitivity analysis (p=0.293). The overall survival (OS) was lower in the FUL group (p=0.0370), particularly for the stage I patients (p=0.046). The independent predictors of OS were FUL (HR=2.148, p=0.006) and pathologic stage (p<0.001).Conclusions: FUL after a gastrectomy was associated with older age, absence of familial support, total gastrectomy, and was related to a poorer OS, particularly in stage I patients.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 1","pages":"33-42"},"PeriodicalIF":0.8,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Magnetically Controlled Capsule Endoscopy for Upper Gastrointestinal Examination]. 磁控胶囊内镜用于上消化道检查。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-01-25 DOI: 10.4166/kjg.2025.149

Dong Jun Oh, Yun Jeong Lim

{"title":"[Magnetically Controlled Capsule Endoscopy for Upper Gastrointestinal Examination].","authors":"Dong Jun Oh, Yun Jeong Lim","doi":"10.4166/kjg.2025.149","DOIUrl":"10.4166/kjg.2025.149","url":null,"abstract":"Esophagogastroduodenoscopy (EGD) is the standard diagnostic modality for upper gastrointestinal (UGI) diseases, but its invasive nature and the risk of sedation-related adverse events limit its applicability in certain patients. Magnetically controlled capsule endoscopy (MCE) is a promising noninvasive alternative, enabling precise active locomotion and complete visualization of the gastric mucosa through external magnetic control. MCE systems have evolved into hand-held and robotic systems, with clinical studies showing diagnostic performance comparable to EGD, along with generally better patient tolerance. Recent studies have shown that a single MCE examination can simultaneously evaluate the UGI tract and small bowel. Advances such as three-dimensional imaging and artificial intelligence have improved diagnostic accuracy and workflow efficiency. Although cost-effectiveness remains a challenge in Korea's healthcare environment, MCE provides a meaningful alternative for patients who are unsuitable for sedated EGD or who prefer a noninvasive modality. With the ongoing technological advances, MCE is expected to evolve into an autonomous, \"One-stop pan-enteric endoscopy\" platform in the near future.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 1","pages":"16-22"},"PeriodicalIF":0.8,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolated Neurofibroma of the Gallbladder and Common Bile Duct Mimicking Malignancy: A Rare Case Report and Review of Literature. 模拟恶性肿瘤的胆囊及胆总管孤立性神经纤维瘤1例报告及文献复习。

IF 0.8

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2026-01-25 DOI: 10.4166/kjg.2025.021

Niket Harsh, Pritesh Kumar N, Aravinda Ps, Pramod Kumar Mishra, Sundeep Singh Saluja, Puja Sakhuja

{"title":"Isolated Neurofibroma of the Gallbladder and Common Bile Duct Mimicking Malignancy: A Rare Case Report and Review of Literature.","authors":"Niket Harsh, Pritesh Kumar N, Aravinda Ps, Pramod Kumar Mishra, Sundeep Singh Saluja, Puja Sakhuja","doi":"10.4166/kjg.2025.021","DOIUrl":"10.4166/kjg.2025.021","url":null,"abstract":"Isolated neurofibromas of the gallbladder (GB) and common bile duct (CBD) are exceptionally rare benign tumors, often mimicking malignancies and posing diagnostic challenges. This paper reports the unique case of a 32-year-old male presenting with right upper quadrant pain, jaundice, and clay-colored stools. Imaging revealed a septate GB with mural thickening, a gallstone, and distal CBD annular thickening, indicating a dual malignancy (GB carcinoma and cholangiocarcinoma). A hepato-pancreatic-duodenectomy was performed because of a suspected malignancy. The histopathology examination unexpectedly revealed spindle cell lesions positive for S100 and neurofilament protein, confirming a primary neurofibroma of the GB and CBD. This first reported case of simultaneous dual-site involvement highlights the diagnostic difficulty because of malignancy mimicry, advocating for intraoperative frozen sections to guide surgical management and avoid overtreatment.","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"86 1","pages":"53-57"},"PeriodicalIF":0.8,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12834633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0